Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
TerminatedNCT01487083
What is this study about?Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.
This study ended early.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–65
- Countries
- United States, France, Austria, + 7 others
- Sponsor
- Denovo Biopharma LLC
CompletedNCT01561898
Official study titleA Long-Term Study of JNS007ER in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 20+
- Countries
- Sponsor
- Janssen Pharmaceutical K.K.
CompletedNCT01456897
Official study titleA Long-term Trial of OPC-34712 in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In Kanto RegionSchizophreniaMedication studyAges 18+
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT01942148
What is this study about?Researchers studied Aripiprazole to find out how it affected psychotic symptoms in children with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Chubu RegionSchizophreniaMedication studyAges 13–17
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
TerminatedNCT01129674
Official study titleA Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia
This study ended early.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States, Croatia, Japan, + 5 others
- Sponsor
- Denovo Biopharma LLC
CompletedNCT00013000
This study has finished and is no longer accepting participants.
Multiple locations, including Washington D.C.SchizophreniaBehavioural studyAges 18–65
- Countries
- United States
- Sponsor
- US Department of Veterans Affairs
CompletedNCT02220712
What is this study about?This study evaluated the safety of OPC-14597 IMD for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Chugoku RegionSchizophreniaMedication studyAges 18–64
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT00505765
Official study titleA Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- University of California, Los Angeles
CompletedNCT04136873
What is this study about?This study evaluated the safety of CVL-231 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Cerevel Therapeutics, LLC
CompletedNCT01870999
What is this study about?This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT00888693
What is this study about?This study evaluated the safety of ABT-288 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–60
- Countries
- Sponsor
- AbbVie
CompletedNCT00922090
Official study titleA Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects With Schizophrenia-An Observational, Multicentric Prospective Study
This study has finished and is no longer accepting participants.
Multiple locations, including BusanSchizophreniaObservational studyAges 18–65
- Countries
- South Korea
- Sponsor
- AstraZeneca